Jefferies Reiterates Buy on Ascendis Pharma
Moderately bullish analyst view; the record contains no new company-specific information.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Moderately bullish analyst view; the record contains no new company-specific information.
What happened, with direct paths to the underlying reporting
Jefferies reiterated its Buy rating and $300 target for ASND versus a posted price of $262.68. The target suggests moderate analyst-estimated upside, but no new supporting catalyst is stated.
Target: $300
Posted price: $262.68
Analyst firm: Jefferies
Analyst: Kelly Shi
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.